Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes an...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-11969-5 |
| _version_ | 1797274335437651968 |
|---|---|
| author | Meng Yang Jingwen Zhang Dongqun Wei Tianyi Yu Zeyu Chen Xin Liu Haitao Zhu |
| author_facet | Meng Yang Jingwen Zhang Dongqun Wei Tianyi Yu Zeyu Chen Xin Liu Haitao Zhu |
| author_sort | Meng Yang |
| collection | DOAJ |
| description | Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes and immune-related adverse events (irAEs). This study aims to retrospectively explore the associations between inflammatory markers and outcomes in patients with postoperative urothelial carcinoma undergoing tislelizumab (PD-1 inhibitor) adjuvant therapy. Methods A retrospective analysis was conducted on 133 patients with postoperative urothelial carcinoma who received tislelizumab adjuvant therapy at the Affiliated Hospital of Xuzhou Medical University from April 2020 to August 2023. The prognostic effects of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) on disease-free survival (DFS) and overall survival (OS) were assessed using Cox regression models. The correlation between inflammatory markers and the onset of irAEs was analyzed using logistic regression models. Results NLR < 5 and MLR < 0.31 were significantly associated with better outcomes compared to NLR >5 and MLR >0.31, respectively. Multivariate analysis revealed that an NLR < 5 was independently associated with better DFS and OS. However, there was no significant effect on the DFS and OS between PLR < 135 and PLR >135. Patients who experienced irAEs had longer DFS and OS. Multivariate analysis demonstrated that irAEs were an independent prognostic risk factor for DFS and OS. There was no significant difference in the occurrence of irAEs among different NLR, PLR, and MLR groups. Conclusion In patients with postoperative urothelial carcinoma receiving tislelizumab adjuvant therapy, the assessment of NLR and MLR before treatment may serve as valuable predictive markers of clinical outcome. |
| first_indexed | 2024-03-07T14:56:57Z |
| format | Article |
| id | doaj.art-e5a4341c6a514a499addd323dfeb3673 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-07T14:56:57Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-e5a4341c6a514a499addd323dfeb36732024-03-05T19:22:48ZengBMCBMC Cancer1471-24072024-02-0124111110.1186/s12885-024-11969-5Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapyMeng Yang0Jingwen Zhang1Dongqun Wei2Tianyi Yu3Zeyu Chen4Xin Liu5Haitao Zhu6Department of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Urology, The Affiliated Hospital of Xuzhou Medical UniversityAbstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes and immune-related adverse events (irAEs). This study aims to retrospectively explore the associations between inflammatory markers and outcomes in patients with postoperative urothelial carcinoma undergoing tislelizumab (PD-1 inhibitor) adjuvant therapy. Methods A retrospective analysis was conducted on 133 patients with postoperative urothelial carcinoma who received tislelizumab adjuvant therapy at the Affiliated Hospital of Xuzhou Medical University from April 2020 to August 2023. The prognostic effects of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) on disease-free survival (DFS) and overall survival (OS) were assessed using Cox regression models. The correlation between inflammatory markers and the onset of irAEs was analyzed using logistic regression models. Results NLR < 5 and MLR < 0.31 were significantly associated with better outcomes compared to NLR >5 and MLR >0.31, respectively. Multivariate analysis revealed that an NLR < 5 was independently associated with better DFS and OS. However, there was no significant effect on the DFS and OS between PLR < 135 and PLR >135. Patients who experienced irAEs had longer DFS and OS. Multivariate analysis demonstrated that irAEs were an independent prognostic risk factor for DFS and OS. There was no significant difference in the occurrence of irAEs among different NLR, PLR, and MLR groups. Conclusion In patients with postoperative urothelial carcinoma receiving tislelizumab adjuvant therapy, the assessment of NLR and MLR before treatment may serve as valuable predictive markers of clinical outcome.https://doi.org/10.1186/s12885-024-11969-5ImmunotherapyUrothelial carcinomaInflammatory markersTislelizumabSurvival |
| spellingShingle | Meng Yang Jingwen Zhang Dongqun Wei Tianyi Yu Zeyu Chen Xin Liu Haitao Zhu Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy BMC Cancer Immunotherapy Urothelial carcinoma Inflammatory markers Tislelizumab Survival |
| title | Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy |
| title_full | Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy |
| title_fullStr | Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy |
| title_full_unstemmed | Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy |
| title_short | Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy |
| title_sort | inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab pd 1 inhibitor adjuvant therapy |
| topic | Immunotherapy Urothelial carcinoma Inflammatory markers Tislelizumab Survival |
| url | https://doi.org/10.1186/s12885-024-11969-5 |
| work_keys_str_mv | AT mengyang inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT jingwenzhang inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT dongqunwei inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT tianyiyu inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT zeyuchen inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT xinliu inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy AT haitaozhu inflammatorymarkerspredictsurvivalinpatientswithpostoperativeurothelialcarcinomareceivingtislelizumabpd1inhibitoradjuvanttherapy |